Analyst Reco. Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 04:00:01 2023-12-04 pm EST			5-day change	1st Jan Change
105.06 ^USD	+1.55%		+3.58%	-5.31%

Dec. 01	Merck: priority review in bladder cancer	CF
Nov. 30	Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deutsche Bank Initiates Coverage on Merck & Company With Buy Rating, $115 Price Target	Nov. 09	MT
ANALYST RECOMMENDATIONS : Apple, ADP, Fortinet, General Motors, S&P...	Nov. 03
Morgan Stanley Adjusts Price Target on Merck & Company to $118 From $115, Maintains Equalweight Rating	Oct. 27	MT
BMO Capital Upgrades Merck & Company to Outperform From Market Perform, Raises Price Target to $132 From $113	Oct. 27	MT
ANALYST RECOMMENDATIONS : Amazon, Comcast, Intel, Merck, Roblox...	Oct. 27
UBS Upgrades Merck & Company to Buy From Neutral, Raises Price Target to $122 From $117	Oct. 20	MT
Morgan Stanley Trims Price Target on Merck to $115 From $116, Maintains Equalweight Rating	Oct. 11	MT
Morgan Stanley Adjusts Price Target on Merck & Company to $116 From $109, Maintains Equalweight Rating	Aug. 02	MT
Merck Swings to Q2 Loss; Raises Guidance Range for 2023 Revenue	Aug. 01	MT
Truist Securities Adjusts Price Target on Merck & Company to $116 From $118, Maintains Buy Rating	Jul. 20	MT
HSBC Initiates Merck & Company With Hold Rating, $123 Price Target	Jul. 14	MT
Atlantic Equities Adjusts Price Target on Merck to $129 From $127, Maintains Overweight Rating	May. 01	MT
Barclays Adjusts Price Target on Merck & Company to $130 From $128, Keeps Overweight Rating	May. 01	MT
UBS Adjusts Merck & Company Price Target to $117 From $108, Maintains Neutral Rating	Apr. 25	MT
Credit Suisse Downgrades Prometheus Biosciences to Neutral From Outperform on Heels of Announced Sale to Merck & Co., Raises Price Target to $200 From $139	Apr. 18	MT
RBC Downgrades Prometheus Biosciences to Sector Perform From Outperform, Lifts Price Target to $200 From $140 on Merck Deal; Speculative Risk Kept	Apr. 18	MT
Citigroup Upgrades Merck & Company to Buy From Neutral, Adjusts Price Target to $130 From $105	Apr. 13	MT
Guggenheim Adjusts Price Target on Merck to $124 From $123, Maintains Buy Rating	Apr. 11	MT
Wells Fargo Downgrades Merck & Company to Equal Weight From Overweight, Adjusts Price Target to $115 From $120	Mar. 13	MT
Berenberg Bank Adjusts Merck & Company Price Target to $130 From $125, Maintains Buy Rating	Mar. 10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Merck & Co., Inc.

Equities

MRK

US58933Y1055

Analyst Reco.

Filters